Anbio Biotechnology Reports Strong 2025 Net Income & Gross Margin Amidst Cash Burn and Auditor Change

summarizeSummary

Anbio Biotechnology reported a 169.9% surge in 2025 net income and an 87.2% gross margin, driven by non-COVID IVD product growth. However, the company experienced negative operating cash flow, a $4 million cash decline, and critically, has not used any of its $7.23 million IPO proceeds. A recent auditor change due to capacity issues and high customer/supplier concentration add to significant risk factors.

check_boxKey Events

• Strong Financial Performance in 2025

  Net income increased by 169.9% to $6.40 million in 2025, up from $2.37 million in 2024. Gross profit margin significantly improved to 87.2% in 2025, compared to 71.9% in 2024 and 50.1% in 2023.

• Critical Liquidity Concerns and Unused IPO Proceeds

  The company reported negative net cash flow from operating activities of $6.74 million in 2025, a sharp decline from positive cash flow in prior years. Despite completing an IPO in February 2025 that generated $7.23 million in net proceeds, the company explicitly stated that none of these proceeds have been used as of December 31, 2025, while its overall cash balance decreased by approximately $4 million.

• Auditor Dismissal Raises Red Flags

  On February 11, 2026, the company dismissed its independent registered public accounting firm, HTL International, LLC, citing a need for a new auditor with 'sufficient available capacity to meet the Company's reporting timeline and ensure the timely completion of the audit' for fiscal year 2025. GGF CPA LTD was appointed as the new auditor.

• High Customer and Supplier Concentration Risks

  In 2025, two customers accounted for 47% of total revenues, with one customer representing 82% of total accounts receivable. Additionally, two suppliers accounted for 100% of the total cost of sales, and one supplier represented 88% of prepayments, indicating significant operational and financial dependencies.

auto_awesomeAnalysis

Anbio Biotechnology's 2025 annual report reveals a significant increase in net income and gross margin, driven by a successful transition to non-COVID-19 related IVD products. However, these positive financial results are overshadowed by critical liquidity concerns, including a substantial negative operating cash flow and a notable decline in overall cash and cash equivalents. A key red flag is the disclosure that the $7.23 million net proceeds from the February 2025 IPO remain entirely unused, suggesting the company is burning through its existing cash reserves. Furthermore, the recent dismissal of its auditor due to 'sufficient available capacity to meet the Company's reporting timeline' raises serious questions about the company's financial reporting and internal controls. High customer and supplier concentration also presents significant business risks. Investors should weigh the strong profitability against these severe liquidity and governance concerns.